| Literature DB >> 34642990 |
Louise Leite Aiquel1, João Pitta2, Georgios N Antonoglou1, Irene Mischak1, Irena Sailer2, Michael Payer1.
Abstract
OBJECTIVE: To investigate the impact of timing of implant placement and loading on implant survival and biological outcomes of multiple-unit implant-supported fixed dental prosthesis (FDPs).Entities:
Keywords: biological outcomes; bone level change; dental implant; implant loading protocols; implant placement protocols; success rates; survival rate
Mesh:
Substances:
Year: 2021 PMID: 34642990 PMCID: PMC9292924 DOI: 10.1111/clr.13860
Source DB: PubMed Journal: Clin Oral Implants Res ISSN: 0905-7161 Impact factor: 5.021
FIGURE 3Funnel plot describing the publication bias assessment
FIGURE 1PRISMA flow diagram illustrating the search strategy
Reasons for exclusion during data extraction
| Main reason for exclusion |
| Studies |
|---|---|---|
| Insufficient data for screening assessment | 67 |
Agliardi et al. (2014) Al Amri et al. (2017) Alasqah et al. (2018) Arlin et al. (2007) Bilhan et al. (2010) Bornstein et al. (2007) Bornstein et al. (2005) Bruschi et al. (2017) Cassetta et al. (2016) Cesaretti et al. (2015) Cochran et al. (2009) Crespi et al. (2010) Degidi et al. (2009a) Degidi et al. (2009b) Ferrini et al. (2018) Glauser et al. (2013) Glibert et al. (2016) Gomez‐Roman et al. (2001) Han et al. (2017) Harel et al. (2013) Jungner et al. (2014) Jungner et al. (2012) Kim et al. (2017) Kokovic et al. (2014) Maddalone et al. (2018) Malchiodi et al. (2011) Montero et al. (2012) Muelas‐Jiménez et al. (2015) Mura (2018) Nicolau et al. (2019) Nicolau et al. (2013) Peñarrocha‐Diago et al. (2012) Pettersson and Sennerby (2013) Polizzi et al. (2000) Polizzi et al. (2013) Pozzi et al. (2012) Pozzi et al. (2015) Rammelsberg et al. (2016) Rocci et al. (2012) Roccuzzo et al. (2018) Rocha et al. (2016) Rossi et al. (2017) Sato et al. (2014) Schliephake et al. (2012) Şener‐Yamaner et al. (2017) Sullivan et al. (2005) Sullivan et al. (2001) Tallarico and Meloni (2017) Testori et al. (2017) Valerón and Valerón (2007) Villa (2018) Wagenberg and Froum (2014) Zembić et al. (2010) Madani et al. (2018) Jung et al. (2016) Cochran et al. (2011a) Cochran et al. (2011b) Esposito et al. ( Bressan et al. (2017) Felice et al. (2019) Gastaldi et al. (2017) Maló and de Araújo Nobre (2016) Nedir et al. (2017) Prosper et al. (2010) Queridinha et al. (2016) Testori et al. (2001) Zuffetti et al. (2016) |
| Mean follow‐up less than 3 years | 3 |
Schwartz‐Arad et al. (2007) Cordaro et al. (2010) Degidi et al. (2008) |
| Less than 10 patients at 3 years | 1 | Ding and Wang (2017) |
| Absence of FPDs supported by ≥2 implants | 7 |
Prati et al. (2016) Kolinsky et al. (2013) Merli et al. (2020) Romeo et al. (2012) Salina et al. (2019) Crespi et al. (2016) Bruschi et al. (2014) |
| Insufficient data do separate different placement protocols | 4 |
Ferrini et al. (2018) Glauser et al. (2016) Glauser et al. (2006) Degidi et al. (2018) |
| Insufficient data to separate single/full mouth from multiple units | 44 |
Pozzi et al. (2014) Anitua et al. (2016) Botticelli et al. (2018) Cresp, et al. (2017) Crespi et al. (2016) Crespi et al. (2010a) Crespi et al. (2010b) Crespi et al. (2014) Degidi et al. (2012) Degidi et al. (2003) Galindo‐Moreno et al. (2014) Liu et al. (2019) Malchiodi et al. (2010) Maló et al. (2011) Maló et al. (2015) Maló et al. (2000) Malo et al. (2007) Maló et al. (2016) Malo et al. (2014) Martinez‐Rodriguez et al. (2018) Mengel et al. (2005) Merli et al. (2020) Mura et al. (2012) Nedir et al. (2004) Öskan et al. (2011) Paredes et al. (2018) Pozzi et al. (2014) Rocci et al. (2003a) Rodrigo et al. (2012) Soydan et al. (2013) Telleman et al. (2017) Wilson et al. (2013) Bettach et al. (2018) Cannizzaro et al. (2008) Crespi et al. (2016) Francetti et al. (2014) Mendonca et al. (2017) Wallkamm et al. (2015) Felice et al. (2018) Felice et al. (2015) Göthberg et al. (2016) Balmer et al. (2018) Temmerman et al. (2019) Mertens et al. (2011) |
| Time of implant placement/loading not reported | 13 |
Al Amri et al. (2017) ArReaje et al. (2019) Baelum et al. (2004) Blus et al. (2010) Bornstein et al. (2003) Bornstein et al. (2010) Cannizzaro et al. (2013) Chiapasco et al. (2020) Ibanes et al. (2003) Östman et al. (2018) Degidi et al. (2010) Harel et al. (2013) Rocci et al. (2003b) |
Overview on study, patient and implant characteristics of included studies
| Study | Study design | Setting/Country | Total number of patients | Drop‐outs |
Presence of smokers Yes/no ( | Patients with history of periodontitis included ( | Reported timing of implant placement | Reported timing of restoration/loading | Type of implant placement and loading protocol | Number of implants | Implant material | Implant brand/Manufacturer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| An et al. ( | Case series (prospective) | University/South Korea | 33 | 0 | NR | NR | NR | Day of implant placement | DPIL | 68 | Titanium | NR |
| Daher et al. ( | RCT (split‐mouth) | University/Lebanon | 24 | 2 | Yes (13) | Yes (NR) | >9 months | Immediately after implant placement | DPIL | 80 | Titanium | NobelActive/Nobel Biocare |
| >9 months | 3.5 months after implant placement | DPDL | 80 | Titanium | ||||||||
| Degidi et al. ( | Observational cohort (prospective) | Private practice/Italy | 24 | 3 | NR | NR | NR | Immediately after implant placement | DPIL | 48 | Titanium | ANKYLOS/Dentsply |
| Fung et al. ( | RCT (split‐mouth) | University/USA | 10 | 0 | Yes (2) | NR | ≥4 months | Within 24 h after implant placement | DPIL | 42 | Titanium | Brånemark System Mk IV TiUnite/Nobel Biocare |
| Göthberg et al. ( | RCT | University/Sweden | 50 | 0 | NR | Yes (NR) | >3 months post‐extraction | Within 48 h after implant placement | DPIL | 78 | Titanium | Brånemark System TiUnite/Nobel Biocare |
| >3 months post‐extraction | 3–4 months after implant placement | DPDL | 72 | Titanium | ||||||||
| Oxby et al. ( | Observational Cohort (prospective) | Private practice/Sweden | 39 | 4 | NR | NR | ≥3 months post‐extraction | Within 60 days after implant placement | DPEL | 107 | Titanium | Astra Tech/Dentsply |
| Immediately post‐extraction | Within 60 days after implant placement | IPEL | 67 | Titanium | ||||||||
| Payer et al. ( | Case Series (prospective) | University/Austria | 24 | 0 | NR | NR | 6 months post‐extraction | Immediately/within 1 week after implant placement | DPIL | 40 | Titanium | Xive/Dentsply |
| Romanos et al. ( | RCT (split‐mouth) | University/Germany | 24 | 4 | NR | NR | NR | Within 24 h after implant placement | DPIL | 36 | Titanium | ANKYLOS/Dentsply |
| NR | 3 months after healing | DPDL | 36 | Titanium | ||||||||
| Si et al. ( | Case Series (retrospective) | University/China | 10 | 0 | Yes (24) | Yes (41) | >3 months after tooth extraction | 3–4 months after healing | DPDL | 21 | Titanium | Straumann AG |
| Siebers et al. ( | Observational cohort (prospective) | Private practice/Germany | 45 | NR | Yes (15) | Yes (45) | Immediately after tooth extraction | Within 48 h after implant placement | IPIL | 20 | Titanium | Camlog; 3i; Lifecore |
| Healed sites | Within 48 h after implant placement | DPIL | 33 | Titanium | ||||||||
| Healed sites | 6 months after implant placement | DPDL | 46 | Titanium | ||||||||
| Spies et al. ( | Observational cohort (prospective) | University/Germany | 13 | 0 | NR | >3 months after tooth extraction | Immediately after implant placement | DPIL | 26 | Zirconia | Metoxit/Ziraldent | |
| Simons et al. ( | Case–control (retrospective)l | University/Belgium | 70 | NR | Yes (29) | Yes (267) | Healed sites | 3–6 months after implant placement | DPDL | 151 | Titanium | Branemark MK III/Nobel Biocare |
| Van Nimwegen et al. ( | RCT | University/Netherlands | 40 | 5 | NR | NR | ≥3 months post‐extraction | ≥3 months after implant placement | DPDL | 70 | Titanium | Nobel Perfect Groovy/Nobel Biocare |
| Vogl et al. ( | RCT | University/Austria | 20 | 0 | NR | NR | Healed sites | Immediately after implant placement | DPIL | 19 | Titanium | Xive/Dentsply |
| Healed sites | Immediately after implant placement | DPIL | 32 | Titanium |
Abbreviation: NR, not reported.
Risk of bias assessments of RCTs based on the Cochrane RoB 2.0 tool
Risk of bias assessments of Cohort studies based on New Castle ‐ Ottawa Quality Assessment Scale
| Study | Representativeness of the exposed cohort | Selection of the non exposed cohort | Ascertainment of exposure | Outcome not present at the start of the study | Comparability of cases and controls | Assessment of outcome | Sufficient follow‐up time for outcomes to occur | Adequacy of follow‐up of cohorts | Total |
|---|---|---|---|---|---|---|---|---|---|
| Degidi et al. ( | * | * | * | * | * | * | * | * | 8 |
| Oxby et al. ( | * | * | * | * | * | * | * | * | 8 |
| Siebers et al. ( | * | * | * | * | * | * | * | 7 | |
| Simons et al. ( | * | * | * | * | * | * | * | 7 | |
| Spies et al. ( | * | * | * | * | * | * | * | * | 8 |
Thresholds for converting the Newcastle‐Ottawa scales to AHRQ standards (good, fair, and poor):
Good quality: 3 or 4 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain.
Fair quality: 2 stars in selection domain AND 1 or 2 stars in comparability domain AND 2 or 3 stars in outcome/exposure domain.
Poor quality: 0 or 1 star in selection domain OR 0 stars in comparability domain OR 0 or 1 stars in outcome/exposure domain.
Risk of bias assessments of Case Series based on Joanna Briggs Institute's Critical Appraisal Checklist
| Study | Were there clear criteria for inclusion in the case series? | Was the condition measured in a standard, reliable way for all participants included in the case series? | Were valid methods used for identification of the condition for all participants included in the case series? | Did the case series have consecutive inclusion of participants? | Did the case series have complete inclusion of participants? | Was there clear reporting of the demographics of the participants in the study? | Was there clear reporting of clinical information of the participants? | Were the outcomes of follow‐up results of cases clearly reported? | Was there clear reporting of the presenting site(s)/clinic (s) demographic information? | Was statistical analysis appropriate? | Overall appraisal |
|---|---|---|---|---|---|---|---|---|---|---|---|
| An et al. ( | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Yes* | Yes | Included |
| Payer et al. ( | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Included |
| Si et al. ( | Yes | Yes | Yes | Yes* | Unclear | Yes | Yes | Yes | Yes | Yes | Included |
Biological outcomes according to the implant placement and loading protocols (NA = not applicable; NR = not reported)
| Study | Placement and loading protocol | Type of loading | Mean ± SD follow‐up (months) | No. implants placed | No. implants available at follow‐up | Implant survival rate | Mean ± SD MBL changes at follow‐up (mm) | Mean ± SD on peri‐implant inflammation (different indexes) | Mean ± SD soft‐tissue recession at follow‐up (mm) | Mean ± SD width KT at follow‐up (mm) | Mean ± SD PI at follow‐up | Mean (SD) PD at follow‐up (mm) | No. of reported biological complications | Rate of biological complications (%) (except implant failure) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| An et al. ( | DPIL | Non‐functional | 36 | 68 | 68 | 100% | 0.42 ± 0.39 | 0.65 ± 0.81 (Gingival Index) | NR | NR | 0.35 ± 0.64 | 2.68 (1.00) | 0 | 0% |
| Daher et al. ( | DPIL | Functional | 36 | 80 | 69 | 95.5% | 0.78 ± 0.72 | NR | NR | NR | NR | NR | 0 | 0% |
| DPDL | NA | 36 | 80 | 71 | 96.3% | 0.91 ± 1.05 | NR | NR | NR | NR | NR | 2 implants with peri‐implantitis | 2.8% | |
| Degidi et al. ( | DPIL | Non‐functional | 36 | 48 | 48 | 100% | 0.57 ± 0.52 | NR | NR | NR | NR | NR | 0 | 0% |
| Fung et al. ( | DPIL | Functional | 36 | 42 | 40 | 95.2% | 0.26 ± 0.44 | 0.25 ± 0.30 (Sulcus Bleeding Index) | NR | NR | NR | 2.82 (0.75) | 0 | 0% |
| Göthberg et al. ( | DPIL | Functional | 60 | 78 | 62 | 94.9% | NR | NR | NR | NR | NR | 3.15 (0.87) | 3 implants with peri‐implantitis | 4.8% |
| DPDL | NA | 60 | 72 | 64 | 97.2% | NR | NR | NR | NR | NR | 3.18 (0.94) |
2 implants with peri‐implantitis 2 implants with fistula | 6.3% | |
| Oxby et al. ( | DPEL | NA | 55 | 107 | 107 | 100% | 0.28 ± 0.88 | NR | NR | NR | NR | NR | 1 implant with soft‐tissue recession | 0.9% |
| IPEL | NA | 55 | 67 | 67 | 100% | 0.34 ± 1.48 | NR | NR | NR | NR | NR | 1 implant with soft‐tissue recession | 1.5% | |
| Payer et al. ( | DPIL | Non‐functional | 96 | 40 | 18 | 95% | 0.88 ± 1.15 | NR | NR | NR | NR | NR | 1 implant with peri‐implantitis | 5.6% |
| Romanos et al. ( | DPIL | Functional | 145.7 ± 10.7 | 36 | 30 | 100% | 0.57 ± 1.06 | 0.07 ± 0.25 (Sulcus Bleeding Index) | 0.30 ± 0.84 | 1.73 ± 1.36 mm | 0.56 ± 0.94 | 2.53 (0.63) | 0 | 0% |
| DPDL | NA | 145.7 ± 10.7 | 36 | 30 | 100% | 1.12 ± 1.30 | 0.00 ± 0.00 (Sulcus Bleeding Index) | 0.20 ±0.48 | 2.00 ± 1.23 mm | 0.43 ± 0.63 | 2.6 (0.50) | 0 | 0% | |
| Si et al. ( | DPDL | NA | 66 | 21 | 19 | 90.5% | NR | NR | NR | NR | NR | NR | 2 implants with peri‐implantitis | 10.5% |
| Siebers et al. ( | DPIL | Both | 45.1 ± 7.2 | 33 | 32 | 97% | 2.15 ± 0.81 | 1.59 ± 1.39 (from 0 to 6) | NR | NR | NR | NR | NR | ‐ |
| DPDL | NA | 55.7 ± 16.2 | 46 | 46 | 100% | 2.46 ± 0.96 | 2.91 ± 2.11 (from 0 to 6) | NR | NR | NR | NR | NR | ‐ | |
| IPIL | Both | 47.64 ± 6.48 | 20 | 17 | 90% | 1.57 ± 0.91 | 1.76 ± 1.79 (from 0 to 6) | NR | NR | NR | NR | NR | ‐ | |
| Simons et al. ( | DPDL | NA | 48 | 151 | 151 | 98.3% | 0.5 ± 0.68 | NR | NR | NR | NR | NR | NR | ‐ |
| Spies et al. ( | DPIL | Non‐functional | 60 | 26 | 26 | 100% | 1.14 ± NR | 1.1 ± NA (modified Bleeding Index) | NR | NR | 0.72 ± NR | NR | 0 | 0 |
| Van Nimwegen et al. ( | DPDL | NA | 60 | 70 | 58 | 97.1% | NR | 40 ± NR (Bleeding Index) | NR | NR | NR | 3.33 (1.73) | 2 implants with peri‐implantitis | 3.4% |
| Vogl et al. ( | DPIL | Functional | 36 | 19 | 17 | 100% | 0.37 ± 0.46 | NR | NR | NR | 1.6 ± 0.7 | NR | 0 | 0% |
| DPIL | Non‐functional | 36 | 32 | 30 | 97% | 0.39 ± 0.47 | NR | NR | NR | 1.6 ± 0.7 | NR | 0 | 0% |
FIGURE 2Forest plot with individual effects and heterogeneity measures
GRADE I‐IV summary‐of‐evidence compilation for each of the four comparisons that could be made between any two placement and loading combinations (DPIL vs. DPDL, IPIL vs. DPDL, DPEL vs. DPDL, IPEL vs. DPDL)
|
| |||||
|---|---|---|---|---|---|
| Delayed placement and immediate loading (DPIL) compared to delayed placement and delayed loading (DPDL) for implant treatment in partially edentulous individuals | |||||
|
| |||||
| Outcomes | Anticipated absolute effects | No. of implants (contributing arm/studies) | Certainty of the evidence (GRADE) | Comments | |
| Weighted effect with delayed placement and delayed loading (DPDL) | Weighted effect with delayed placement and immediate loading (DPIL) | ||||
| Rx bone loss around the implant platform assessed with: Radiographic image | The mean rx bone loss around the implant platform was 1.68 mm ± 0.97 | The mean rx bone loss around the implant platform was 0.71 mm ± 0.66 | 676 implants (4 RCTs, 6 observational studies) |
⨁◯◯◯ VERY LOW | Immediate loading after delayed placement seems to reduce potential bone loss after loading. Follow‐up period varied from 3 years up to 15 years |
| Bleeding on probing assessed with: Sulcus Bleeding Index | The mean SBI was 0.066 (±0.253) | The mean SBI was 0.00 (±0.00) | 60 implants (1 RCT) |
⨁⨁◯◯ LOW | Immediate loading after delayed placement does not seems to affect the Sulcus Bleeding Index. Follow‐up was 15 years |
| Peri‐implant probing depth | The mean peri‐implant pocket depth was 3.12 mm ± 1.08 | The mean peri‐implant pocket depth was 2.83 mm ± 0.92 | 352 (4 RCTs, 1 observational studies) |
⨁◯◯◯ VERY LOW | Peri‐implant pocket depth does not exhibit substantial difference between immediate and delayed loading after delayed implant placement |
| Peri‐implantitis prevalence assessed with: Radiographic and clinical examination | The mean percentage of implants with peri‐implantitis was 3.5% | The mean percentage of implants with peri‐implantitis was 0.9% | 535 (4 RCTs, 4 observational studies) |
⨁◯◯◯ VERY LOW | Evidence is scarce on peri‐implantitis and low rates were reported in the included studies. This could be in part due to poor reporting of the study of the clinical examination. Follow‐up period varied from 3 years up to 15 years |
| Mucositis | No muscositis was reported in all studies with data on peri‐implantitis | 535 (4 RCTs, 4 observational studies) |
⨁◯◯◯ VERY LOW | Evidence is scarce on mucositis. No cases were reported in the included studies but this could be in part due to poor reporting of the study of the clinical examination. Follow‐up period varied from 3 years up to 15 years | |
| Survival rate assessed with: Radiographic and clinical examination | The mean survival rate was 98.1.2% | The mean survival rate was 97.2% % | 879 implants (6 RCTs, 7 observational studies) |
⨁◯◯◯ VERY LOW | Both delayed and immediate loading after delayed placement after delayed implant placement present high survival rates. Follow‐up period varied from 3 years up to 15 years |
|
| |||||
All studies except for one RCT (Göthberg et al., 2018) showed from some concerns to high risk of bias; only 3 direct comparisons.
The study Romanos et al. (2014) was rated with high risk of bias.
Based on withing study comparisons.
Based on within and between study comparisons
All studies except for one RCT showed from some concerns to high risk of bias.
Based on between study comparisons.